Working… Menu
Help guide our efforts to modernize
Send us your comments by March 14, 2020.
Trial record 4 of 8 for:    NAFCILLIN AND cloxacillin

A Phase 3 Telavancin Staphylococcus Aureus (S. Aureus) Bacteremia Trial

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02208063
Recruitment Status : Terminated (Halted due to lack of statistical power. No safety concerns identified. Enrolled subjects were allowed to complete scheduled study activities.)
First Posted : August 4, 2014
Last Update Posted : January 15, 2019
Information provided by (Responsible Party):
Cumberland Pharmaceuticals

Brief Summary:
This is a multicenter, randomized, open-label, noninferiority trial of telavancin versus standard IV therapy control (e.g., vancomycin, daptomycin, anti-staphylococcal penicillin (PCN), or cefazolin) in the treatment of subjects with complicated Staphylococcus aureus (S. aureus) bacteremia and SA right-sided infective endocarditis (RIE).

Condition or disease Intervention/treatment Phase
Bacteremia Drug: Telavancin Drug: Vancomycin Drug: Daptomycin Drug: Synthetic penicillin Drug: Cefazolin Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 121 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 3 Multicenter, Randomized, Open-label, Clinical Trial of Telavancin Versus Standard Intravenous Therapy in the Treatment of Subjects With Staphylococcus Aureus Bacteremia Including Infective Endocarditis
Actual Study Start Date : December 2014
Actual Primary Completion Date : April 12, 2018
Actual Study Completion Date : April 12, 2018

Arm Intervention/treatment
Experimental: Telavancin
7.5 mg/kg administered intravenously once every 24 hours daily over 60 minutes
Drug: Telavancin
Active Comparator: Standard of care
Vancomycin, Daptomycin, synthetic penicillin or Cefazolin
Drug: Vancomycin
Drug: Daptomycin
Other Name: Cubicin

Drug: Synthetic penicillin
Other Names:
  • Nafcillin
  • Oxacillin
  • Cloxacillin

Drug: Cefazolin

Primary Outcome Measures :
  1. Clinical response (success or failure) [ Time Frame: Up to 8 weeks ]
    Clinical response (success or failure) for subjects with uncomplicated bacteremia receiving 2 to 4 weeks of treatment at test of cure (TOC) (38 [+/-2] days after randomization), for subjects with complicated bacteremia receiving 4 to 6 weeks of treatment at test of cure (TOC) (52 [+/-2] days after randomization), and for subjects with endocarditis receiving 6 weeks of treatment at test of cure (TOC) (52 [+/-2] days after randomization)

Secondary Outcome Measures :
  1. Development of new metastatic foci of infection [ Time Frame: After Day 8 ]
  2. Clearance of bacteremia [ Time Frame: Up to 8 weeks ]
    For subjects with a positive S. aureus blood culture on Day 1, time to all blood cultures negative for S. aureus for two days in succession

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • 18 years of age or older with at least one blood culture positive for S. aureus within 48 hours before randomization
  • At least one of the following signs or symptoms of bacteremia:

    • Temperature ≥ 38.0°C
    • WBC count > 10,000 or < 4,000 cells/µL or > 10% immature neutrophils (bands)
    • Tachycardia (heart rate > 90 bpm)
    • Tachypnea (respiratory rate > 20 breaths/min)
    • Hypotension (systolic blood pressure < 90 mmHg)
    • Signs or symptoms of localized catheter-related infection
  • At enrollment, subjects must have either 1) known right-sided infective endocarditis by Modified Duke's criteria 2) known complicated bacteremia, demonstrated as signs or symptoms of metastatic foci of S. aureus infection or 3) at least one risk factor for complicated bacteremia.

Exclusion Criteria:

  • Treatment with any potentially effective (anti-staphylococcal) systemic antibiotic for more than 60 hours within 7 days before randomization. EXCEPTION: Documented resistance to the prior systemic antibacterial therapy
  • Presence of an infection source that will not be managed or controlled within the first 3 days of study drug treatment
  • Presence of prosthetic cardiac valve or cardiac device (eg, implantable cardioverter defibrillator [ICD]), permanent pacemaker, or cardiac valve support ring)
  • Known or suspected left-sided infective endocarditis (LIE), by Modified Duke Criteria. NOTE: Right-sided infective endocarditis (RIE) is permitted
  • Known or suspected osteomyelitis or meningitis. NOTE: Evidence of metastatic complications related to the primary infection such as right-sided endocarditis, septic arthritis, septic pulmonary emboli are permitted. S. aureus pneumonia is permitted
  • Confirmed evidence (identification or gram stain) of a mixed polymicrobial infection with a Gram-negative pathogen that requires non-study antibiotic treatment with agent(s) that have activity against Gram-negative pathogens

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02208063

Layout table for location information
United States, Ohio
Remington-Davis Clinical Research
Columbus, Ohio, United States, 43215
Sponsors and Collaborators
Cumberland Pharmaceuticals
Layout table for investigator information
Study Director: Medical Monitor Cumberland Pharmaceuticals, Inc.

Layout table for additonal information
Responsible Party: Cumberland Pharmaceuticals Identifier: NCT02208063    
Other Study ID Numbers: 0112
First Posted: August 4, 2014    Key Record Dates
Last Update Posted: January 15, 2019
Last Verified: January 2019
Keywords provided by Cumberland Pharmaceuticals:
Staphylococcus aureus
Additional relevant MeSH terms:
Layout table for MeSH terms
Bacterial Infections
Systemic Inflammatory Response Syndrome
Pathologic Processes
Anti-Bacterial Agents
Anti-Infective Agents